Pomalidomide improves the function of CD133-or HER2-specific CAR T cells  

作　　者：ZHIXIONG WANG NA RISU JIAYU FU HUI LIU GUOMIN ZHOU QIAN LIU YAN ZOU JIAXING TANG LONG LI XUEKAI ZHU 

机构地区：[1]Ma’anshan University,Ma’anshan,243100,China [2]Division of Health Science,Graduate School of Medicine,Osaka University,Osaka,565-0871,Japan [3]School of Medical Instrument and Food Engineering,University of Shanghai for Science and Technology,Shanghai,200093,China [4]Shanghai Institute for Advanced Immunochemical Studies(SIAIS),ShanghaiTech University,Shanghai,201210,China

出　　处：《BIOCELL》2021年第1期157-165,共9页生物细胞（英文）

基　　金：supported by the National Key R&D Program(2019YFA0111001)of China.

摘　　要：Chimeric antigen receptor(CAR)T-cell therapy is mostly limited to hematological malignancies and has a poor effect on solid tumors.CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as pomalidomide,so the use of pomalidomide may improve the effect of CAR T cells on solid tumors.In this study,CD133-or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells in vitro.We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T cells to kill tumor cells and increase the cytokine secretion of CD133-CAR T cells and HER2-CAR T cells.Also,pomalidomide was shown to induce down-regulation of protein levels of IL-2 transcriptional repressors Aiolos and Ikaros in CAR T cells.This study suggests that the combination of pomalidomide and CAR T cells may be a new strategy for the treatment of solid tumors.

关 键 词：Chimeric antigen receptor Actimid Solid tumor IMMUNOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]